Abivax S.A.

Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that leverage the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases ⁵⁴. The company's primary focus is on inflammatory bowel diseases (IBD), specifically ulcerative colitis (UC) and Crohn's disease (CD) ⁵⁴.

The core business model revolves around the development and potential commercialization of its lead drug candidate, obefazimod, and expanding its pipeline with follow-on compounds based on its miR-124 platform ⁵⁵. Revenue generation is currently not from product sales, as the company has no approved products, and it anticipates not generating product sales revenue for the next several years ⁹. The company's ability to generate revenue depends on successfully completing development, obtaining regulatory approvals, and commercializing its drug candidates, either alone or through collaborations ⁹.

Abivax's lead drug candidate, obefazimod, is an oral small molecule in Phase 3 clinical development for moderately to severely active UC and in Phase 2b clinical development for CD ⁵⁵. Obefazimod's novel mechanism of action (MOA) involves enhancing the expression of micro-RNA miR-124, a natural regulator of the inflammatory response, which controls inflammation progression and restores immune system homeostasis without causing broader immunosuppression [54, 57]. This MOA is believed to modulate multiple inflammatory pathways simultaneously, potentially leading to more durable efficacy in lifelong conditions like IBD ⁵⁴. The company is also exploring potential combination therapy opportunities in IBD with obefazimod and generating follow-on compounds based on its miR-124 platform ⁵⁵.

For the fiscal year ended December 31, 2025, Abivax reported a net loss of €336.1 million ⁹. This follows net losses of €176.2 million in 2024 and €147.7 million in 2023 ⁹. As of December 31, 2025, the company carried forward accumulated tax losses of €912.9 million ⁹. The company did not incur any material capital expenditures for the years ended December 31, 2025, 2024, and 2023, other than in the ordinary course of business ⁵⁴.

Year-over-year, the net loss significantly increased from €176.2 million in 2024 to €336.1 million in 2025, representing a substantial expansion of operating losses ⁹. The company's accumulated tax losses have also grown, indicating continued investment in research and development without corresponding product revenue ⁹.

During the reported period, Abivax announced top-line data from its two Phase 3 ABTECT induction trials for moderately to severely active UC in July 2025 ⁵⁹. In the pooled analysis of these trials, obefazimod 50 mg achieved a 16.4% placebo-adjusted clinical remission rate, and obefazimod 25 mg achieved a 13.2% placebo-adjusted clinical remission rate, both statistically significant (p<0.0001) ⁵⁹. The overall rates of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for obefazimod were similar to placebo, with headache being the most frequent TEAE (20.8-25.8% for 50 mg, 14.5-15.6% for 25 mg, 5.7% for placebo) ⁶¹. The company also initiated a Phase 2b clinical trial in patients with CD in the fourth quarter of 2024 ⁶³. Additionally, three Phase 1 clinical trials were completed in 2025 to assess the tolerability and safety profile of obefazimod, including two drug-drug interaction trials (enrolling 24 and 36 healthy volunteers, respectively) and a trial in participants with mild and moderate hepatic impairment (enrolling 30 participants) ⁶⁵. In September 2024, initial preclinical combination data of obefazimod with etrasimod in a mouse model of IBD showed synergistic and statistically significant reduction of several cytokines (TNFa, IL-17, IL-6, IFNg) [56, 65].

Abivax's management expects to report top-line data from its Phase 3 ABTECT maintenance trial in late second quarter of 2026 ⁶⁵. Subject to positive data from this trial, the company currently expects to submit its New Drug Application (NDA) with the FDA in the fourth quarter of 2026 ⁶⁵.

A major growth area for Abivax is the advancement of obefazimod through pivotal clinical trials to establish it as a potential preferred advanced therapy for IBD ⁵⁵. The company believes the induction data from its Phase 3 clinical trials, showing a pooled 16.4% placebo-adjusted clinical remission rate after 8 weeks of treatment and a differentiated clinical response rate across various patient populations, positions obefazimod as a highly competitive advanced therapy choice for moderately to severely active UC, if approved ⁵⁵. Furthermore, the strength of the maintenance data from its Phase 2b trial, which demonstrated a clinical remission rate of 53% and a clinical response rate of 73% at week 96 with no new adverse safety signals, if confirmed in the ongoing Phase 3 maintenance trial, could further solidify obefazimod's position as a potential treatment of choice for all UC patient treatment lines ⁵⁵. The estimated market opportunity for UC was approximately $9.2 billion in worldwide sales in 2025 and is projected to reach $21.8 billion in worldwide sales in 2032, with U.S. sales expected to grow from $6.0 billion in 2025 to $14.9 billion by 2032 ⁵⁶. The company estimates that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, representing a significant market for a safe, efficacious, oral therapy ⁵⁶. For Crohn's disease (CD), a Phase 2b clinical trial was initiated in the fourth quarter of 2024, with top-line induction data expected in the fourth quarter of 2026 [55, 63]. The estimated market opportunity for CD was approximately $15.2 billion in worldwide sales in 2025 and is expected to reach $19.4 billion in worldwide sales in 2032, with U.S. sales of approximately $10.5 billion in 2025 ⁵⁶. The company estimates approximately 480,000 moderate-to-severe CD patients in the United States, out of an estimated 800,000 patients ⁵⁷.

Another growth vector is the potential for combination therapy in IBD with obefazimod ⁵⁶. The company believes obefazimod's oral administration and novel mechanism of action make it an attractive candidate for combination with other oral or injectable agents, potentially improving induction and remission efficacy over monotherapy ⁵⁶. Initial preclinical combination data of obefazimod with etrasimod in a mouse model of IBD, announced in September 2024, showed improved body weight protection, Disease Activity Index, and a synergistic and statistically significant reduction of several cytokines (TNFa, IL-17, IL-6, IFNg) [56, 65]. The company is investigating potential synergies with agents targeting other MOAs (a4b7, IL-23, PDE-4, and ahR) and expects additional preclinical data to support decision-making on a combination agent in 2026 ⁵⁶.

Abivax is also leveraging its library of miR-124 enhancers to expand its pipeline in chronic inflammatory diseases ⁵⁶. A research and development program is ongoing to generate new potential drug candidates based on the miR-124 platform, with the first obefazimod follow-on candidate selection expected in 2026 [56, 66]. The company may also consider R&D portfolio additions through external scientific and medical partnerships in chronic inflammatory diseases at preclinical or clinical stages ⁵⁶.

Operationally, the company is in the process of further optimizing and scaling up its supply chain for obefazimod to ensure capacity for expected commercial supply, if approved by the FDA or foreign regulatory authorities ⁶⁸. Additionally, Abivax is establishing a second source manufacturer for obefazimod to ensure continuity of product supply ⁶⁸. The company's outsourcing strategy for manufacturing allows it to focus resources on drug candidate development and third-party management, avoiding investment in expensive manufacturing facilities and equipment ⁶⁸.

Regarding capital allocation, the company intends to invest its future earnings, if any, to fund its growth ⁵³. As of December 31, 2025, the theoretical exercise or vesting of all outstanding founder’s share warrants (BCE), share warrants (BSA), and free shares (AGA), excluding securities held by financing entities, would result in the issuance of 8,857,084 potential new ordinary shares, representing a hypothetical dilution of 11.3% based on the outstanding share capital ¹¹. The general meeting of June 6, 2025, delegated authority to the board of directors for capital increases and/or issues of securities giving access to capital, with a total maximum nominal amount of capital increases set at €250,000 and a total maximum nominal amount of debt securities at €150,000,000 ¹¹. Shares issued or allotted in equity incentive plans may not exceed 10% of the share capital on a fully diluted basis as of June 6, 2025, and as of December 31, 2025, these plans represented 9.2% of the share capital on a fully diluted basis ¹¹.

Abivax faces significant risks, including its status as a clinical-stage company with no approved products and a history of considerable losses, reporting net losses of €336.1 million in 2025, €176.2 million in 2024, and €147.7 million in 2023, with accumulated tax losses of €912.9 million as of December 31, 2025 ⁹. The company is heavily dependent on the success of its lead drug candidate, obefazimod, and clinical failure can occur at any stage, with earlier trial results not necessarily predictive of future outcomes [13, 15]. Material weaknesses in internal controls over financial reporting persist as of December 31, 2025, related to risk assessment, control activities, information and communication, monitoring activities, and control environment, which could adversely affect financial reporting accuracy and timeliness ¹⁰. Current equity agreements and convertible debt instruments may dilute equity, with a hypothetical dilution of 11.3% from outstanding warrants and free shares as of December 31, 2025 ¹¹. The company's ability to exclusively commercialize drug candidates may decrease if intellectual property rights are not adequately protected or are insufficient, and it may be sued for infringement or misappropriation of third-party intellectual property [17, 33, 34]. International operations expose the company to risks such as foreign currency exchange rate fluctuations, differing payor reimbursement regimes, and reduced intellectual property protection in certain countries [22, 23]. Global economic conditions, including geopolitical developments like the Russia-Ukraine war, could materially adversely impact demand for drug candidates, supply chains, and access to financing [22, 32]. The company relies on a small number of third-party suppliers and manufacturers, in some cases single-source, for raw materials and clinical batches, creating dependence ²³. Furthermore, the company is subject to a restrictive and changing regulatory framework, including healthcare laws and regulations, anti-corruption laws, and export control laws, with potential for significant penalties for non-compliance [38, 39, 42]. The market price of its equity securities may be volatile, influenced by factors such as financial performance, competition, and regulatory announcements ⁵².

Management's overall tone emphasizes a strategic focus on advancing obefazimod through pivotal clinical trials and establishing it as a potential preferred advanced therapy for IBD, starting with moderately to severely active UC and CD ⁵⁵. They highlight the strength of the Phase 3 induction data for obefazimod in UC, noting a pooled 16.4% placebo-adjusted clinical remission rate after 8 weeks of treatment, and a highly differentiated placebo-adjusted clinical response rate across various patient populations, with no major safety concerns ⁵⁵. Management also points to the promising maintenance data from the Phase 2b trial, which showed a 53% clinical remission rate and 73% clinical response rate at week 96, with no new adverse safety signals, as a basis for positioning obefazimod as a potential treatment of choice for all UC patient treatment lines, if confirmed in the ongoing Phase 3 maintenance trial ⁵⁵. Key strategic priorities include the expectation to report top-line data from the Phase 3 ABTECT maintenance trial in late second quarter of 2026, with a subsequent NDA submission to the FDA anticipated in the fourth quarter of 2026, subject to positive data ⁶⁵. Additionally, management is focused on exploring potential combination therapy opportunities in IBD with obefazimod, citing initial preclinical data showing synergistic effects, and leveraging its miR-124 enhancers to expand the pipeline with new drug candidates, with an obefazimod follow-on candidate selection expected in 2026 ⁵⁶.